CD40L-GVAX |
GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF |
Phase 2 Clinical |
University Of South Florida |
Leukemia; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Adenocarcinoma of Lung; Lung Neoplasms; Adenocarcinoma; Melanoma |
Details
|
Giloralimab |
ABBV-927 |
Phase 2 Clinical |
Abbvie Inc |
Solid tumours; Head and Neck Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BI-655064 |
BI-655064 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis |
Details
|
Mitazalimab |
ADC-1013; JNJ-7107; JNJ-64457107 |
Phase 2 Clinical |
Alligator Bioscience Ab |
Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal |
Details
|
Sotigalimab |
APX-005M; EPI-0050; APX-005 |
Phase 2 Clinical |
Epitomics Inc |
Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Skin Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Microsatellite Instability; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Iscalimab |
CFZ-533; NVP-CFZ533; OM11-62-MF |
Phase 2 Clinical |
Novartis Pharma Ag |
Rejection of renal transplantation; Myasthenia Gravis; Diabetes Mellitus, Type 1; Rejection of liver transplantation; Sjogren's Syndrome; Arthritis, Rheumatoid; Lupus Nephritis; Graves Disease; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa |
Details
|
Anti-CD40 ChiLob7/4 (BioNTech) |
|
Phase 2 Clinical |
Biontech Se |
Head and Neck Neoplasms; Pancreatic Neoplasms |
Details
|
CDX-1140 |
CDX-1140 |
Phase 2 Clinical |
Celldex Therapeutics |
Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Sarcoma; Breast Neoplasms; Osteosarcoma; Cholangiocarcinoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Merkel Cell; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Uveal melanoma |
Details
|
Bleselumab |
4D-11; ASKP-1240 |
Phase 2 Clinical |
Kyowa Hakko Kogyo Co Ltd |
Rejection of renal transplantation; Rejection of organ transplantation; Psoriasis; Glomerulosclerosis, Focal Segmental |
Details
|
Tecaginlimab |
BNT-312; GEN-1042 |
Phase 2 Clinical |
Genmab A/S |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Ravagalimab |
ABBV-323; PR-1629977 |
Phase 2 Clinical |
Abbvie Inc |
Sjogren's Syndrome; Colitis, Ulcerative |
Details
|
CD40.RBDv vaccin(LinKinVax) |
|
Phase 2 Clinical |
LinKinVax, ANRS, Emerging Infectious Diseases, Vaccine Research Institute (VRI), France |
Coronavirus Disease 2019 (COVID-19) |
Details
|
DFI-105 |
DFI105; DFI-105 |
Phase 2 Clinical |
Diabetes Free Inc |
Diabetes Mellitus, Type 2 |
Details
|
HPV CD40 HVac |
|
Phase 2 Clinical |
LinKinVax |
Head and Neck Neoplasms; Oropharyngeal Neoplasms |
Details
|
Cifurtilimab |
SEA-CD40 |
Phase 2 Clinical |
|
Head and Neck Neoplasms; Lymphoma, B-Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma |
Details
|
MIL-97 |
MIL-97 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Solid tumours; Pancreatic Neoplasms |
Details
|
Dalnicastobart |
LVGN7409; LVGN-7409 |
Phase 2 Clinical |
Lyvgen Biopharma(HK)Ltd |
Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
2141-V11 |
2141-V11 |
Phase 2 Clinical |
The Rockefeller University |
Solid tumours; Ganglioglioma; Neoplasms; Skin Neoplasms; Glioblastoma; Urinary Bladder Neoplasms; Glioma |
Details
|
YH-003 |
YH-003; YH003 |
Phase 2 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Solid tumours; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma |
Details
|
Abiprubart |
KPL-404 |
Phase 2 Clinical |
Primatope Therapeutics Inc |
Arthritis, Rheumatoid |
Details
|
NJA-730 |
NJA-730; NJA-730a; NJA-730b |
Phase 1 Clinical |
Napajen Pharma |
Autoimmune Diseases |
Details
|
Selicrelumab |
RG-7876; RO-7009789 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms; Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) |
|
Phase 1 Clinical |
Baylor College Of Medicine |
Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
ABBV-428 |
ABBV-428; ABBV428 |
Phase 1 Clinical |
Abbvie Inc |
Solid tumours |
Details
|
MEDI-5083 |
MEDI-5083 |
Phase 1 Clinical |
Astrazeneca Plc, Medimmune |
Solid tumours |
Details
|
NG-350A |
NG-350A |
Phase 1 Clinical |
Akamis Bio Ltd |
Neoplasms, Glandular and Epithelial; Neoplasm Metastasis |
Details
|
SL-172154 |
SL-172154 |
Phase 1 Clinical |
Shattuck Labs Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute |
Details
|
LNF-1901 |
LNF-1901; LNF1901 |
Phase 1 Clinical |
Lunan Pharmaceutical Group Co |
Neoplasms |
Details
|
B-901 |
B-901; B901 |
Phase 1 Clinical |
FutureGen Biopharm (Beijing) Co Ltd |
Solid tumours |
Details
|
SHR-7367 |
SHR7367; SHR-7367 |
Phase 1 Clinical |
Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Neoplasms |
Details
|
SHR-1704 |
SHR-1704 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Neoplasms |
Details
|
IMB-071703 |
IMB-071703; IMB071703 |
Phase 1 Clinical |
Beijng Immunoah Pharma Tech Co Ltd |
Solid tumours |
Details
|
ILB-2101 |
ILB-2101 |
Phase 1 Clinical |
Innolake Biopharm (Hangzhou) Co Ltd |
Neoplasms |
Details
|
HBM-9027 |
HBM-9027; HBM9027 |
Phase 1 Clinical |
Harbour Biomed |
Solid tumours; Neoplasms |
Details
|
BSI-038 |
BSI-038 |
Phase 1 Clinical |
Boaoxin Biotechnology(Nanjing) Co Ltd |
Solid tumours |
Details
|
TQB-2916 |
TQB2916; TQB-2916 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms |
Details
|
RO-7300490 |
RO-7300490; RG-6189 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms |
Details
|
CD40.HIVRI.Env Vaccine |
|
Phase 1 Clinical |
Anrs, LinKinVax |
HIV Infections |
Details
|
Inezetamab |
AMG-994 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours |
Details
|
BMS-986325 |
Y 12XX-hz28-P238K |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Sjogren's Syndrome |
Details
|
OPT-101 |
|
Phase 1 Clinical |
Op-T LLC |
Diabetes Mellitus, Type 1 |
Details
|
NWY-001(Biocytogen Pharmaceuticals) |
NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) |
Phase 1 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd |
Solid tumours; Hematologic Neoplasms; Neoplasms |
Details
|